MA47451A - Pyridines à substitution hétéroarylsulfonyle et leur utilisation dans le traitement du cancer - Google Patents
Pyridines à substitution hétéroarylsulfonyle et leur utilisation dans le traitement du cancerInfo
- Publication number
- MA47451A MA47451A MA047451A MA47451A MA47451A MA 47451 A MA47451 A MA 47451A MA 047451 A MA047451 A MA 047451A MA 47451 A MA47451 A MA 47451A MA 47451 A MA47451 A MA 47451A
- Authority
- MA
- Morocco
- Prior art keywords
- heterarylsulfonyl
- pyridines
- substitution
- cancer treatment
- cancer
- Prior art date
Links
- RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical compound NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000006467 substitution reaction Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455639P | 2017-02-07 | 2017-02-07 | |
| US201762594799P | 2017-12-05 | 2017-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47451A true MA47451A (fr) | 2019-12-18 |
Family
ID=61226606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047451A MA47451A (fr) | 2017-02-07 | 2018-02-07 | Pyridines à substitution hétéroarylsulfonyle et leur utilisation dans le traitement du cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11028067B2 (fr) |
| EP (1) | EP3580215A1 (fr) |
| JP (1) | JP2020507625A (fr) |
| KR (1) | KR20190115013A (fr) |
| CN (1) | CN110382486A (fr) |
| AU (1) | AU2018218519B2 (fr) |
| BR (1) | BR112019016223A2 (fr) |
| CA (1) | CA3051537A1 (fr) |
| MA (1) | MA47451A (fr) |
| MX (1) | MX392000B (fr) |
| WO (1) | WO2018146469A1 (fr) |
| ZA (1) | ZA201904967B (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201514021D0 (en) | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
| KR20190115011A (ko) | 2017-02-07 | 2019-10-10 | 오블리크 세러퓨틱스 에이비 | 설피닐피리딘 및 암의 치료에서 이의 용도 |
| CA3051538A1 (fr) | 2017-02-07 | 2018-08-16 | Oblique Therapeutics Ab | Pyridines a substitution heterocyclylsulfonyle et leur utilisation dans le traitement du cancer |
| MA47458A (fr) | 2017-02-07 | 2019-12-18 | Oblique Therapeutics Ab | Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer |
| CN111867587A (zh) * | 2018-02-12 | 2020-10-30 | 信达制药公司 | 用于治疗癌症的硫氧还蛋白还原酶抑制剂 |
| US20200115389A1 (en) | 2018-09-18 | 2020-04-16 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE4643T1 (de) * | 1979-12-19 | 1983-09-15 | Duphar International Research B.V | Nitrothiophene, verfahren zur herstellung der verbindungen sowie fungizide und/oder bakterizide zusammensetzungen auf der basis dieser verbindungen. |
| US4456469A (en) | 1980-03-07 | 1984-06-26 | E. I. Du Pont De Nemours And Company | Pyridyl sulfone herbicides |
| AU543161B2 (en) | 1980-03-07 | 1985-04-04 | E.I. Du Pont De Nemours And Company | Pyrimidine or s.triazine derivatives |
| US4791127A (en) | 1985-10-07 | 1988-12-13 | Nippon Kayaku Kabushiki Kaisha | Alkanesulfonate derivatives and their use as insecticides, acaricides or nematicides |
| DE3812177A1 (de) | 1988-04-13 | 1989-10-26 | Bayer Ag | 2-phenylsulfinyl-nitro-pyridine, verfahren zu ihrer herstellung und ihre verwendung |
| AU2395095A (en) | 1994-04-29 | 1995-11-29 | G.D. Searle & Co. | Method of using (h+/k+) atpase inhibitors as antiviral agents |
| DE19531148A1 (de) | 1995-08-24 | 1997-02-27 | Basf Ag | Fungizide Pyridin-2-yl-Derivate |
| AU6926596A (en) | 1995-08-24 | 1997-03-19 | Basf Aktiengesellschaft | N-heterocyclic compounds, intermediate products used to prepare them, agents containing them and their use in antifungal applications |
| JP2002507197A (ja) | 1997-05-30 | 2002-03-05 | ビーエーエスエフ アクチェンゲゼルシャフト | 置換チオピリジン |
| US6284923B1 (en) | 1997-08-22 | 2001-09-04 | Tularik Inc | Substituted benzene compounds as antiproliferative and cholesterol lowering action |
| WO1999018096A1 (fr) | 1997-10-02 | 1999-04-15 | Merck & Co., Inc. | Inhibiteurs de la prenyl-proteine transferase |
| US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6191170B1 (en) | 1998-01-13 | 2001-02-20 | Tularik Inc. | Benzenesulfonamides and benzamides as therapeutic agents |
| DE69906397T2 (de) | 1998-01-16 | 2004-02-19 | F. Hoffmann-La Roche Ag | Benzosulfonderivate |
| DK1259485T3 (da) | 2000-02-29 | 2006-04-10 | Millennium Pharm Inc | Benzamider og beslægtede inhibitorer for faktor Xa |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| WO2003068744A1 (fr) | 2002-02-18 | 2003-08-21 | Ishihara Sangyo Kaisha, Ltd. | Derives de la pyridine ou leurs sels, et inhibiteurs de production de citokine renfermant ces derives |
| US20030236287A1 (en) | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
| US7037902B2 (en) | 2002-07-03 | 2006-05-02 | Receptron, Inc. | Affinity small molecules for the EPO receptor |
| WO2005007621A2 (fr) | 2003-05-30 | 2005-01-27 | Rigel Pharmaceuticals, Inc. | Inhibiteurs de ligase d'ubiquitine |
| ATE415397T1 (de) | 2004-06-04 | 2008-12-15 | Arena Pharm Inc | Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen |
| US20060019967A1 (en) | 2004-07-21 | 2006-01-26 | Su-Ying Wu | SARS CoV main protease inhibitors |
| GB0426313D0 (en) | 2004-12-01 | 2005-01-05 | Merck Sharp & Dohme | Therapeutic agents |
| WO2006083692A2 (fr) | 2005-01-28 | 2006-08-10 | Mount Sinai Schoool Of Medicine | Procédés d'identification de modulateurs de bromodomaines |
| GB0504828D0 (en) | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
| EP1976495A2 (fr) | 2006-01-06 | 2008-10-08 | Aarhus Universitet | Composes agissant sur le transporteur de la serotonine |
| JP2009535307A (ja) | 2006-04-28 | 2009-10-01 | アベキサ・リミテッド | インテグラーゼ阻害剤３ |
| EP2061472A4 (fr) * | 2006-05-22 | 2010-12-22 | Thioredoxin Systems Ab | Inhibiteurs de thioredoxine reductase bacterienne et procédés d'utilisation afférents |
| SG183036A1 (en) | 2007-07-17 | 2012-08-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| CN101723932B (zh) | 2008-10-31 | 2013-11-20 | 北京以岭生物工程技术有限公司 | 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途 |
| WO2010138820A2 (fr) * | 2009-05-28 | 2010-12-02 | President And Fellows Of Harvard College | Composés de n,n'-diarylurée et de n,n'-diarylthiourée utilisés en tant qu'inhibiteurs de l'initiation de la traduction |
| CA2771190C (fr) | 2009-08-17 | 2020-01-21 | Memorial Sloan-Kettering Cancer Center | Composes de liaison a une proteine de choc thermique, compositions et procedes pour les fabriquer et les utiliser |
| US9206125B2 (en) | 2010-02-10 | 2015-12-08 | Public University Corporation Yokohama City University | Use of compound binding to mSin3B that specifically binds to neuron restrictive silencer factor (NRSF) |
| CN102206172B (zh) | 2010-03-30 | 2015-02-25 | 中国医学科学院医药生物技术研究所 | 一组取代双芳基化合物及其制备方法和抗病毒应用 |
| EP2609089A1 (fr) | 2010-08-27 | 2013-07-03 | Universität des Saarlandes | Inhibiteurs sélectifs de la 17-bêta-hydroxystéroïde déshydrogénase de type 1 |
| US9539256B2 (en) | 2012-02-10 | 2017-01-10 | The Board Of Regents Of The University Of Texas System | Modulators of exchange proteins directly activated by cAMP (EPACS) |
| JP6393322B2 (ja) | 2013-07-10 | 2018-09-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規なキラル窒素−リン配位子及びアルケン類の不斉水素化のためのその使用 |
| CN104672214B (zh) | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
| CN105503827B (zh) | 2014-10-11 | 2019-09-24 | 上海翰森生物医药科技有限公司 | Egfr抑制剂及其制备方法和用途 |
| CN105085483B (zh) | 2015-06-04 | 2019-01-01 | 湖北生物医药产业技术研究院有限公司 | 激酶抑制剂及其应用 |
| CN104987324B (zh) | 2015-06-04 | 2018-05-04 | 湖北生物医药产业技术研究院有限公司 | 作为alk抑制剂的嘧啶衍生物 |
| GB201514021D0 (en) | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
| MA47458A (fr) | 2017-02-07 | 2019-12-18 | Oblique Therapeutics Ab | Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer |
| CA3051538A1 (fr) | 2017-02-07 | 2018-08-16 | Oblique Therapeutics Ab | Pyridines a substitution heterocyclylsulfonyle et leur utilisation dans le traitement du cancer |
| KR20190115011A (ko) | 2017-02-07 | 2019-10-10 | 오블리크 세러퓨틱스 에이비 | 설피닐피리딘 및 암의 치료에서 이의 용도 |
-
2018
- 2018-02-07 JP JP2019563697A patent/JP2020507625A/ja active Pending
- 2018-02-07 CA CA3051537A patent/CA3051537A1/fr active Pending
- 2018-02-07 AU AU2018218519A patent/AU2018218519B2/en not_active Ceased
- 2018-02-07 EP EP18705461.4A patent/EP3580215A1/fr not_active Withdrawn
- 2018-02-07 KR KR1020197024694A patent/KR20190115013A/ko not_active Ceased
- 2018-02-07 US US16/484,039 patent/US11028067B2/en not_active Expired - Fee Related
- 2018-02-07 BR BR112019016223A patent/BR112019016223A2/pt not_active IP Right Cessation
- 2018-02-07 CN CN201880010198.8A patent/CN110382486A/zh active Pending
- 2018-02-07 MX MX2019009351A patent/MX392000B/es unknown
- 2018-02-07 WO PCT/GB2018/050343 patent/WO2018146469A1/fr not_active Ceased
- 2018-02-07 MA MA047451A patent/MA47451A/fr unknown
-
2019
- 2019-07-29 ZA ZA2019/04967A patent/ZA201904967B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019128045A3 (fr) | 2021-03-09 |
| CN110382486A (zh) | 2019-10-25 |
| ZA201904967B (en) | 2023-12-20 |
| AU2018218519A1 (en) | 2019-08-15 |
| KR20190115013A (ko) | 2019-10-10 |
| MX2019009351A (es) | 2019-09-19 |
| MX392000B (es) | 2025-03-21 |
| AU2018218519B2 (en) | 2021-08-05 |
| US20200223819A1 (en) | 2020-07-16 |
| CA3051537A1 (fr) | 2018-08-16 |
| US11028067B2 (en) | 2021-06-08 |
| WO2018146469A1 (fr) | 2018-08-16 |
| EP3580215A1 (fr) | 2019-12-18 |
| JP2020507625A (ja) | 2020-03-12 |
| BR112019016223A2 (pt) | 2020-04-07 |
| RU2019128045A (ru) | 2021-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43163A (fr) | Polypeptides à domaine extracellulaire cd80 et leur utilisation dans le traitement du cancer | |
| MA47452A (fr) | Pyridines à substitution hétérocyclylsulfonyle et leur utilisation dans le traitement du cancer | |
| MA45122A (fr) | Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer | |
| MA52886A (fr) | Composés de purinone et leur utilisation dans le traitement du cancer | |
| MA47451A (fr) | Pyridines à substitution hétéroarylsulfonyle et leur utilisation dans le traitement du cancer | |
| MA47458A (fr) | Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer | |
| SI3661954T1 (sl) | Muteini interlevkina-21 in postopki zdravljenja | |
| PL3303632T3 (pl) | Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze | |
| MA42915A (fr) | Pyridines et leur utilisation dans le traitement du cancer | |
| EP3673947A4 (fr) | Cathéter et ensemble cathéter | |
| HUE054548T2 (hu) | Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében | |
| MA39960A (fr) | Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer | |
| EP2831278A4 (fr) | Aptamères dirigés contre pdgf et vegf et leur utilisation dans le traitement d'états à médiation par pdgf et vegf | |
| EP3431102A4 (fr) | Médicament thérapeutique induisant des lésions cellulaires à utiliser dans le traitement du cancer | |
| EP3937980A4 (fr) | Miarn modifiés et leur utilisation dans le traitement du cancer | |
| IL255119B (en) | Therapeutic pooled blood apoptotic cell preparations and uses thereof | |
| MA47450A (fr) | Sulfinylpyridines et leur utilisation dans le traitement du cancer | |
| EP2948188A4 (fr) | Imagerie neuronale et traitement | |
| SI3319612T1 (sl) | Oksisteroli in postopki za uporabo le-teh | |
| MA41316A (fr) | Gènes de détermination du sexe et leur utilisation en reproduction | |
| EP3448263A4 (fr) | Traitement électrothérapeutique | |
| EP3331984A4 (fr) | Systèmes et procédés de traitement d'allogreffe rapides | |
| MA41587A (fr) | N-(4-hydroxy-4-méthylcyclohexyl)-4-phénylbenzènesulfonamides et n-(4-hydroxy-4-méthylcyclohexyl)-4-(2-pyridyl)benzènesulfonamides et leur utilisation thérapeutique | |
| EP3258964A4 (fr) | Détection et traitement de tumeurs malignes dans le snc | |
| EP3713289A4 (fr) | Procédé de traitement de requêtes, et entité correspondante |